Chaozhong has extensive experience in cell-related product development such as immortalized cell lines, stable reporter cell lines, and cell-based assays development. He is currently the CTO of Cell Therapy at Simnova Biotherapeutics. Prior to that he was the VP of Product Development, Cell Therapy at Wugen and Head, Vector Cell Bank and Analytics at Takeda.… Continue reading Chaozhong Zou Ph.D.
Gopal joined Targazyme Inc. in September 2021 and began his stint as a part time Project Manager and Grant Administrator. He subsequently onboarded as a full-time employee at Targazyme Inc. Prior to that he was an R&D Scientist at ShieldT3 LLC in Chicago, IL, where he was involved in developing and validating novel molecular diagnostic… Continue reading Gopal Ramakrishnan Ph.D.
Dr. Jakubowski came to TargaZyme after a long career in both big and small pharmaceutical. She started her career at Bristol Myers, working with dermatological products and then moving to the Bristol Myers Research Center in Wallingford, CT, where she built and led a regulatory group that focused on building a single, international dossier that… Continue reading Audrey Jakuwboski, PhD
Dr. Srivastava is a Clinician-Scientist and a global leader in cancer drug development and an executive leader who has managed global clinical trials with multi-million-dollar budgets and has mediated the merger and acquisition of several pharma companies. He has led more than 150 global phase 1-4 clinical trials involving several cancers and as an oncologist,… Continue reading Ashok Srivastava, MD, PhD, MBA
Mr. Ma leads our international business development initiatives, leveraging his expertise in investment banking and M&A transactions. Prior to joining Targazyme, he was an investment banker responsible for M&A and licensing transactions at Suntrust Robinson Humphrey, Aaron-Bell International and Evergreen Advisors. Mr. Ma graduated from the United States Military Academy at Westpoint with a Bachelor… Continue reading Philip Ma, MBA
Dr. Zloza is a renowned outcomes-driven leader in the fields of immunology and cancer (immuno-oncology) translational and clinical research with more than 15 years of experience in the academic and biotechnology sectors. He has a history of leading teams from concept to clinical trial, and most recently led a discovery program as Senior Director of… Continue reading Andrew Zloza, MD, PhD
Mr. Lang is a highly accomplished finance professional with a wealth of expertise in corporate control, strategic advisory, and tax planning. With a keen focus on financial performance and exceptional leadership skills, Mr. Lang drives business success across diverse industries. Experienced in GAAP, financial statement management, process improvement, and audit, Mr. Lang provides actionable insights… Continue reading Sam Lang, MBA
Dr. Jung is a biostatistician with a balanced experience in collaboration with cancer investigators and methodological research. He has been collaborating on cancer studies for over 30 years in the cooperative cancer trial group setting (NCCTG, ACOSOG, CALGB, Alliance) as well as within an NCI – designated cancer center setting (Mayo Cancer Center, Indiana University… Continue reading Sin-Ho Jung, PhD
Dr. Bissonnette is a drug discovery and development scientist with over 25 years of experience in oncology drug discovery and development, with particular emphasis and interest in immuno-oncology and translational medicine. He has extensive hands-on experience acting as PI on both preclinical (pharmacology) and nonclinical (safety) trials, focused on targeted oncology, immuno-oncology and inflammation therapeutics.… Continue reading Reid Bissonnette PhD
Dr. Olson is a biotechnology industry professional with broad scientific and operational experience, having a focus in process development, manufacturing and other CMC related activities for many clinical and commercial products. With over forty years of experience, he is a true veteran, having enabled the production of virtually every class and size of biological product… Continue reading Chuck Olson, PhD